Innate Pharma SA (IPHYF)
OTHER OTC:IPHYF
Holding IPHYF?
Track your performance easily

Innate Pharma SA (IPHYF) Cash flow

27 Followers

Innate Pharma SA Cash Flow

IPHYF's free cash flow for Q4 2023 was $―. For the 2023 fiscal year, IPHYF's free cash flow was decreased by $-6.12M and operating cash flow was $―. See a summary of the company’s cash flow.
Cash Flow
TTM
Dec 23Dec 22Dec 21Dec 20Dec 19
Operating Cash Flow
-$ -32.56M$ -28.57M$ -58.46M$ -51.77M$ 34.92M
Investing Cash Flow
-$ 20.63M$ 1.88M$ -917.00K$ -13.37M$ -62.12M
Financing Cash Flow
-$ -1.97M$ -1.83M$ 26.82M$ -1.18M$ 77.77M
Cash Flow From Discontinued Operation
------
Other Cash Adjustment Inside Changein Cash
------
End Cash Position
-$ 70.61M$ -28.57M$ -29.52M$ 136.79M$ 202.89M
Income Tax Paid Supplemental Data
------
Interest Paid Supplemental Data
------
Issuance Of Capital Stock
-$ 395.00K$ 198.00K$ 499.00K$ 0.00$ 66.01M
Issuance Of Debt
-$ -2.36M$ -2.03M$ 26.63M$ 1.36M$ 13.90M
Repayment Of Debt
-$ -2.36M$ -2.03M$ -2.07M$ -2.25M$ -1.98M
Free Cash Flow
-$ -34.70M$ -28.57M$ -58.46M$ -63.05M$ -30.48M
Domestic Sales
------
Foreign Sales
------
Currency in USD

Innate Pharma SA Cash Flow

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis